MI-UPSTREAM-SECURITY
10.4.2024 16:07:32 CEST | Business Wire | Press release
Upstream Security, a leading provider of cybersecurity extended detection and response (XDR) for connected vehicles and IoT, today announced it received an investment from Cisco Investments. The proliferation of complex IoT devices in the Mobility, Automotive, and Transportation sectors introduces unprecedented operational efficiencies, data-driven services and solutions, and exceptional customer experience. However, advanced connectivity and software-defined components also open the door for large-scale cyber risks, threatening business availability and data integrity.
Upstream already protects millions of mobility connected vehicles and IoT devices worldwide, offering a cloud-based multi-layered approach to extended detection and response.
“We are thrilled to welcome Cisco Investments to our group of investors,” states Yoav Levy, Upstream Security Co-founder and CEO. “This investment provides a unique opportunity to deepen our impact on the IoT sector, and more specifically Mobility, Automotive and Transportation.”
This investment by Cisco Investments amplifies the need for purpose-built IoT cybersecurity solutions that will safeguard the mobility and IoT ecosystem across the entire development and production lifecycle.
“Together with our partners, Cisco is enabling automobile manufacturers across the globe to provide mission-critical, secure connectivity as cars transform into data centers on wheels," says Cisco Investments vice president, Aleem Rizvon. “With an expected 95% of new vehicles having embedded connectivity by the year 2030, we can also expect a rise in automotive cybersecurity threats. Investing in solutions, to ensure the right safeguards for secure connectivity and operation are in place, is critical to instill the trust needed for wide adoption of the technology, not just in the automotive segment, but more broadly for other IoT applications, as well.
Disrupting the IoT Cybersecurity Landscape
Upstream’s cloud-based IoT XDR platform analyzes, in real-time, the contextual state of physical IoT assets and their connected ecosystem, to holistically identify and mitigate cyber risks. The Platform is agentless, requiring no installation of software or hardware, enabling rapid deployment and comprehensive coverage of devices already in production.
The Platform ingests, parses, and normalizes vast amounts of connected vehicle data, IoT protocols, telematics, API transactions, and other data streams from tens of millions of devices, endpoints, and application consumers. This data enables the creation of unique digital twins—near real-time representations of devices and endpoints, facilitating holistic and effective detection. By monitoring devices, services, and overall asset behavior, the Platform detects both known and unknown anomalies based on proprietary ML-powered models.
Coupled with a purpose-built vehicle security operation center (vSOC), dedicated for monitoring and investigating connected vehicles and IoT cyber threats, Upstream provides a holistic suite of cybersecurity solutions and services to enable customers to proactively identify and remediate cyber threats. Utilizing Upstream’s Ocean AI, Generative AI-powered capabilities, accelerates the investigation remediation process.
About Upstream Security
Upstream provides a cloud-based data management platform purpose-built for mobility and IoT, delivering unparalleled cybersecurity extended detection and response (XDR) and data-driven applications. The Upstream Platform secures more than 25 million connected vehicles and IoT devices and is trusted by large vehicle manufacturers and IoT service providers.
Upstream recently published its 2024 Automotive Cybersecurity Report, providing a detailed analysis of the cyber landscape across the Automotive and Mobility ecosystem, emerging risks, and the evolving regulatory landscape.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410994590/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom